M
Mohamed Ben Hassel
Publications - 9
Citations - 2834
Mohamed Ben Hassel is an academic researcher. The author has contributed to research in topics: Temozolomide & Survival rate. The author has an hindex of 7, co-authored 9 publications receiving 2464 citations.
Papers
More filters
Journal ArticleDOI
Adjuvant Whole-Brain Radiotherapy Versus Observation After Radiosurgery or Surgical Resection of One to Three Cerebral Metastases: Results of the EORTC 22952-26001 Study
Martin Kocher,Riccardo Soffietti,Ufuk Abacioglu,Salvador Villà,François Fauchon,Brigitta G. Baumert,L. Fariselli,Tzahala Tzuk-Shina,Rolf-Dieter Kortmann,Christian Carrie,Mohamed Ben Hassel,Mauri Kouri,Egils Valeinis,Dirk van den Berge,Sandra Collette,Laurence Collette,Rolf-Peter Mueller +16 more
TL;DR: After radiosurgery or surgery of a limited number of brain metastases, adjuvant WBRT reduces intracranial relapses and neurologic deaths but fails to improve the duration of functional independence and overall survival.
Journal ArticleDOI
A European Organisation for Research and Treatment of Cancer Phase III Trial of Adjuvant Whole-Brain Radiotherapy Versus Observation in Patients With One to Three Brain Metastases From Solid Tumors After Surgical Resection or Radiosurgery: Quality-of-Life Results
Riccardo Soffietti,Martin Kocher,Ufuk Abacioglu,Salvador Villà,François Fauchon,Brigitta G. Baumert,L. Fariselli,Tzahala Tzuk-Shina,Rolf-Dieter Kortmann,Christian Carrie,Mohamed Ben Hassel,Mauri Kouri,Egils Valeinis,Dirk van den Berge,Rolf P. Mueller,Gloria Tridello,Laurence Collette,Andrew Bottomley +17 more
TL;DR: This study shows that adjuvant WBRT after surgery or radiosurgery of a limited number of brain metastases from solid tumors may negatively impact some aspects of HRQOL, even if these effects are transitory.
Journal ArticleDOI
Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study
Brigitta G. Baumert,Brigitta G. Baumert,Monika E. Hegi,Martin J. van den Bent,Andreas von Deimling,Thierry Gorlia,Khê Hoang-Xuan,Alba A. Brandes,Guy Kantor,Martin J.B. Taphoorn,Mohamed Ben Hassel,Christian Hartmann,Christian Hartmann,Gail Ryan,David Capper,Johan M. Kros,Sebastian Kurscheid,Sebastian Kurscheid,Wolfgang Wick,Roelien H. Enting,Michele Reni,Brian Thiessen,Frédéric Dhermain,Jacoline E C Bromberg,Loïc Feuvret,Jaap C. Reijneveld,Olivier Chinot,J.M.M. Gijtenbeek,John P. Rossiter,Nicolas Dif,Carmen Balana,Jose Bravo-Marques,Paul Clement,Christine Marosi,Tzahala Tzuk-Shina,Robert A Nordal,Jeremy Rees,Denis Lacombe,Warren P. Mason,Roger Stupp,Roger Stupp +40 more
TL;DR: There was no significant difference in outcome of the overall patient population treated with either radiotherapy alone or TMZ chemotherapy alone, and further data maturation is needed for overall survival analyses and evaluation of the full predictive impact of the molecular subtypes for individualized treatment choices.
Journal ArticleDOI
Parenchymal pineal tumors : A clinicopathological study of 76 cases
François Fauchon,Anne Jouvet,Philippe Paquis,Ghislaine Saint-Pierre,Carmine Mottolese,Mohamed Ben Hassel,Laurent Chauveinc,Jean-Pierre Sichez,Jacques Philippon,Michel Schlienger,Eric Bouffet +10 more
TL;DR: A retrospectively reviewed series of 76 consecutive patients from 12 European centers with histologically proven tumors with pineal parenchymal tumors highlighted the prognostic features of PPT and may help to determine treatment strategies based on radiologic and pathologic characteristics.
Journal ArticleDOI
Health-related quality of life in patients with high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study
Jaap C. Reijneveld,Martin J.B. Taphoorn,Corneel Coens,Jacoline E C Bromberg,Warren P. Mason,Khê Hoang-Xuan,Gail Ryan,Mohamed Ben Hassel,Roelien H. Enting,Alba A. Brandes,Antje Wick,Olivier Chinot,Michele Reni,Guy Kantor,Brian Thiessen,Martin Klein,Eugenie Verger,Christian Borchers,Peter Hau,Michael Back,Anja Smits,Vassilis Golfinopoulos,Thierry Gorlia,Andrew Bottomley,Roger Stupp,Brigitta G. Baumert,Brigitta G. Baumert,Brigitta G. Baumert +27 more
TL;DR: The results do not support the choice of temozolomide alone over radiotherapy alone in patients with high-risk low-grade glioma and the results for two key secondary endpoints: HRQOL and global cognitive functioning are reported.